-
November 22, 2012
The European market for drugs to treat Alzheimer's disease (AD) is set to grow from a value of $1.80 billion in 2012 to $4.78 billion by 2019, increasing at a compound annual growth rate (CAGR) of 15.1% during the period, according to new forecasts.
Full story
-
October 22, 2012
Recommendations from EMA advisors include rejecting Lundbeck’s Acrescent for Alzheimer’s disease, and approving Novo Nordisk's diabetes drugs Tresiba and Ryzodeg.
Full story
-
July 19, 2012
The percentage of dementia patients being prescribed antipsychotic drugs in England fell from 17% in 2006 to 7% in 2011, according to the first-ever national primary care audit on the issue.
Full story
-
May 29, 2012
Lundbeck says its investigational Alzheimer's disease drug Lu AE58054 has met its primary endpoint in a mid-stage study
Full story
-
April 17, 2012
The NHS in England spent £8.81 billion on prescription drugs supplied through primary care last year, down 0.1% from £8.83 billion in 2010, official figures show.
Full story
-
March 23, 2012
The FDA has been accused of breaching its "own regulatory standard" by approving a new dose of Eisai and Pfizer's blockbuster Alzheimer's drug Aricept in 2010, despite it causing more side effects and not showing significant superiority over the original doses
Full story
-
February 28, 2012
Only 41% of people in England and Wales who are living with dementia have had a diagnosis, a figure which is 2% up on last year, according to new research from Alzheimer's Society.
Full story
-
November 01, 2011
Astellas Pharma has posted a strong set of financials, but fellow Japanese drugmakers Daiichi Sankyo and Eisai have suffered profit declines
Full story
-
June 02, 2011
Teva Pharmaceutical Industries is reportedly looking at pacts with Indian drugmakers, as the Israeli firm's version of Eisai/Pfizer's Alzheimer's drug Aricept is one of many approved by the FDA
Full story
-
April 26, 2011
Eisai has suffered a setback with the news that US regulators have turned down a patch version of its Alzheimer’s disease blockbuster Aricept.
Full story